Patents by Inventor Stephen K. Doberstein

Stephen K. Doberstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optimized Fc variants and methods for their generation
    Patent number: 10183999
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized Fc variants and methods for their generation
    Patent number: 10184000
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 22, 2019
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • OPTIMIZED FC VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20180141997
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: June 26, 2017
    Publication date: May 24, 2018
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
    Publication number: 20170349643
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 7, 2017
    Applicant: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin G.P. Wong, Ge Wu, Hongbing Zhang
  • Optimized Fc variants and methods for their generation
    Patent number: 9714282
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 25, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20160347837
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20160347825
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20160318993
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: May 6, 2016
    Publication date: November 3, 2016
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized FC variants and methods for their generation
    Patent number: 9353187
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: May 31, 2016
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
    Publication number: 20160096876
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: October 7, 2015
    Publication date: April 7, 2016
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Methods of treating disease with FGFR1 fusion proteins
    Patent number: 9192683
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: November 24, 2015
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Optimized Fc variants and methods for their generation
    Patent number: 9193798
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: November 24, 2015
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC
    Patent number: 9173957
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: November 3, 2015
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20150079082
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Gregory Alan LAZAR, Arthur Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • OPTIMIZED FC VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20140377256
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: May 23, 2014
    Publication date: December 25, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
    Publication number: 20140370021
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Application
    Filed: June 14, 2013
    Publication date: December 18, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized Fc variants and methods for their generation
    Patent number: 8858937
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 14, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • Optimized Fc variants and methods for their generation
    Patent number: 8809503
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 19, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
  • COMPOSITIONS AND METHODS OF USE FOR MGD-CSF IN DISEASE TREATMENT
    Publication number: 20140170145
    Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
    Type: Application
    Filed: October 8, 2013
    Publication date: June 19, 2014
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
  • Optimized fc variants and methods for their generation
    Patent number: 8734791
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: May 27, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John R. Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa